Literature DB >> 3156750

N-(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654), a putative 5-HT1 agonist, causes constriction of arteriovenous anastomoses and dilatation of arterioles.

P D Verdouw, H M Jennewein, J Mierau, P R Saxena.   

Abstract

Using 3H-ligands and radioactive microspheres we studied the binding characteristics and the effects on the distribution of carotid arterial blood flow of n-(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654). The compound had a Ki value of 32 nM (5-HT: 8 nM) on 5-HT1 but no or very weak affinity for 5-HT2, alpha 1- and alpha 2-adrenoceptor sites in rat cerebral cortex homogenates. Intracarotid infusions of BEA 1654 (0.1-1.0 mg X kg-1 X min-1) were nearly equieffective in untreated and treated (phentolamine plus ketanserin) pigs in redistributing carotid arterial blood towards the nutrient compartment (particularly the skin and ears) at the expense of shunting via arteriovenous anastomoses (AVAs). In view of the high and selective affinity of BEA 1654 to 5-HT1 binding sites, the similarity of pharmacological responses between 5-HT and BEA 1654, and the ineffectiveness of antagonists of 5-HT2 and alpha-adrenergic receptors to block the AVA constriction and arteriolar dilatation caused by both 5-HT and BEA 1654, we conclude that these effects are mediated by 5-HT1 receptors. The vast difference between the ratios of Ki values for 5-HT1 binding sites and of the pharmacologically effective doses of BEA 1654 and 5-HT suggests that either BEA 1654 may be a partial agonist of 5-HT1 receptors or, while the drug binds with both subsets of 5-HT1 receptors, it is only one type which mediates the pharmacological response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156750     DOI: 10.1016/0014-2999(85)90259-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation of tachycardia by 5-HT1-like receptors.

Authors:  P R Saxena; E J Mylecharane; J Heiligers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

2.  Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: evidence for the presence of "5-hydroxytryptamine1-like" receptors.

Authors:  P R Saxena; D J Duncker; A H Bom; J Heiligers; P D Verdouw
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

3.  Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.

Authors:  M O den Boer; C M Villalón; J P Heiligers; P P Humphrey; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

4.  5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor.

Authors:  A H Bom; D J Duncker; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

5.  Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors.

Authors:  A H Bom; J P Heiligers; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

6.  GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein.

Authors:  P P Humphrey; W Feniuk; M J Perren; H E Connor; A W Oxford; L H Coates; D Butina
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

7.  Nisoldipine and perfusion of post-stenotic myocardium in conscious pigs with different degrees of concentric stenosis.

Authors:  D J Duncker; J P Heiligers; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

8.  Carotid haemodynamics in pigs during infusions of 8-OH-DPAT: reduction in arteriovenous shunting is mediated by 5-HT1-like receptors.

Authors:  A H Bom; P D Verdouw; P R Saxena
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.